You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
To enable the use of saliva in addition to other types of samples, Sysmex requested a change to a marketing approval it obtained in March.
By running FCS Express on the CyFlow Cube V2m device, Sysmex Parec believes customers will benefit from an analysis software that allows advanced reporting capabilities and data export options.
Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.
The company believes cytogeneticists will adopt its panel to get high-quality SNV and CNV data in a single assay.
The reagent is used for the detection of cytokeratin 19 mRNA in surgically removed sentinel lymph nodes in order to diagnose lymph node metastasis.
The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
The two companies have been working together since February and now are formalizing plans to develop and test new products.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.
The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.